Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» hemophilia A
hemophilia A
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Endpoints
Tue, 05/22/18 - 09:58 am
Biomarin
hemophilia A
valrox
Roche drug dramatically reduces bleeds in key hemophilia tests
Reuters
Mon, 05/21/18 - 10:13 am
Roche
Hemlibra
clinical trials
hemophilia A
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
BioPharma Dive
Tue, 12/12/17 - 10:50 pm
ASH17
Spark Therapeutics
gene therapy
Biomarin
hemophilia A
SPK-8011
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
BioPharma Dive
Sat, 12/9/17 - 02:31 pm
ASH17
Biomarin
gene therapy
hemophilia A
valoctocogene
FDA Approves Genentech Hemophilia Drug, But Adds Safety Warning
Xconomy
Fri, 11/17/17 - 10:19 am
Genentech
FDA
hemophilia A
Hemlibra
With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy
Endpoints
Sun, 10/29/17 - 10:04 am
Biomarin
gene therapy
BMN 270
hemophilia A
Bayer files longer-acting bleeding candidate to FDA
Fierce Biotech
Fri, 09/1/17 - 10:15 am
Bayer
FDA
BAY94-9027
hemophilia A
Bioverativ taps patient social network for input on hemophilia trial design
Fierce Pharma
Thu, 08/24/17 - 10:41 pm
Bioverativ
social media
clinical trials
patients
hemophilia A
Biogen
Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab
Endpoints
Thu, 08/24/17 - 09:53 am
Shire
Roche
emicizumab
hemophilia A
Spark offers a glimpse of efficacy in first two hemophilia A gene therapy patients
Endpoints
Wed, 08/2/17 - 09:39 am
Spark Therapeutics
hemophilia A
gene therapy
SPK-8011
Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger
Endpoints
Mon, 06/26/17 - 09:54 am
Roche
hemophilia A
ACE910
emicizumab
clinical trials
Shire writes off a shot at long-acting hemophilia drug after small study flops
Endpoints
Mon, 05/22/17 - 09:55 am
Shire
hemophilia A
SHP656
Xenetic Biosciences
clinical trials
Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
Endpoints
Thu, 05/11/17 - 11:21 am
Pfizer
gene therapy
hemophilia
Sangamo BioSciences
SB-525
hemophilia A
Roche claims that its interim update on hemophilia A drug is positive. But it’s hard to gauge.
Endpoints
Mon, 04/17/17 - 11:07 am
Roche
hemophilia A
emicizumab
Roche gears up to enter loaded hemophilia A drug market
Medical Marketing and Media
Thu, 02/16/17 - 03:11 pm
Roche
hemophilia A
emicizumab
Roche Finds Safe Haven In Emicizumab
Seeking Alpha
Sat, 12/24/16 - 12:13 pm
Roche
emicizumab
hemophilia A
Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success
Endpoints
Thu, 12/22/16 - 11:40 am
Roche
hemophilia A
ACE910
emicizumab
Hey, wait a second. What about Roche’s PhIII hemophilia A drug?
Endpoints
Fri, 07/29/16 - 11:24 am
Roche
hemophilia A
Chugai
emicizumab
ACE910
Germany's Bayer wins U.S. FDA approval for hemophilia A therapy
Yahoo/Reuters
Thu, 03/17/16 - 09:57 am
Bayer
FDA
hemophilia A
Kovaltry
5 Reasons Roche Thinks It Can Outclass the Competition
Motley Fool
Fri, 11/13/15 - 04:23 pm
Roche
atezolizumab
ACE910
hemophilia A
lampalizumab
dry macular degeneration
ocrelizumab
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »